Ustekinumab
Based on 4 publication(s) in Google Scholar
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.83%
- CAS. Nr.: 815610-63-0
- Molecular Weight:145.63 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ustekinumab
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Imaging
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
Biologische Aktivität
Human IgG1 kappa
Human
|
IL-12 |
IL-23 |
Ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells[1]. Ustekinumab is a human IgG1 kappa (κ) monoclonal antibody against the IL-12/IL-23 p40 subunit that prevents its interaction with IL-12Rβ1, thereby blocking subsequent signaling. The FcRn affinities at pH 6.0 fell in a narrow range for all 11 antibodies. The equilibrium dissociation constant (KD) is calculated relative to Ustekinumab (Ustekinumab=1.0)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IL-12 beta Protein, Human (HEK293, Fc, HY-P73160) can bind Ustekinumab. The EC50 for this effect is 13.6 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling IL-12B (red) with Ustekinumab (HY-P9909). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS. Nr. 815610-63-0
-
Appearance Liquid
-
Molecular Weight 145.63 kDa
-
Color Colorless to light yellow
-
SMILES
[Ustekinumab]
-
Synonyms
CNTO-1275; L04AC05; TT-20
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Probiotics Bi-Enzymatic Cascade Repair System for Editing the Inflammatory Microenvironment to Boost Probiotic Therapy in Inflammatory Bowel Disease. [Abstract]2024 Dec 6:e2412429. PMID: 39641224
Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429. [Abstract]
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. Daily change in body weight for each group, including Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Measurements of colonic tissue length in various groups on day 10. DAI changes throughout 10 days, calculated as the total of the stool consistency (0–3), fecal bleeding (0–4), and weight loss (0–4) indexes.
Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429. [Abstract]
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Mice colonic sections stained with HE on day 10 following the indicated treatments.
Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429. [Abstract]
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Colonic MPO levels on day 10.) Colonic TNF-α, IL-6, and IL-1β levels on day 10.
-
Nat Immunol
2021 Sep;22(9):1107-1117. PMID: 34385713
Ustekinumab purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2021 Sep;22(9):1107-1117. [Abstract]
Flow cytometry quantification of cell viability and lipid ROS of HC neutrophils cultured in vitro with 20% SLE serum supplemented with anti-CXCL11 (0.1, 1, 5 µg/ml) or Ustekinumab (0.1, 1, 10 µg/ml) for 16 hours.
-
Int J Biol Macromol
An activatable antibody conjugate for cold tumors: Synergistic ferroptosis and immunotherapy via photodynamic PD-L1 targeting. [Abstract]2026 Feb;342(Pt 1):150155. PMID: 41519335 -
Protokoll
HUVECs are grown on calibrated glass coverslips to a confluency of 80%. Subsequently, cells are incubated with 200 µg/mL Ustekinumab AlexaFluor488 and Briakinumab AlexaFluor594 for 20 min at 37°C, pH 7.3, washed three times, and chased in fresh medium for an additional 20 min before fixation. Antibodies are directly labeled. FcRn binding is quality controlled by SPR analysis. Cells are then counterstained with anti-FcRn monoclonal antibody DVN22, followed by anti-mouse secondary antibodies conjugated to AlexaFluor647. Imaging is performed on a Leica SP8 confocal microscope[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (261 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Montepaone M, et al. Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. Open Access Rheumatol. 2014 Feb 20;6:7-13. [Content Brief]
[2]. Schoch A, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Ustekinumab Related Classifications
HY-P9909 Related Classifications
Powered by Bioz